June 21 (Reuters) - Eli Lilly and Co LLY.N:
LILLY'S ORAL GLP-1, ORFORGLIPRON, SHOWED COMPELLING EFFICACY AND A SAFETY PROFILE CONSISTENT WITH INJECTABLE GLP-1 MEDICINES, IN COMPLETE PHASE 3 RESULTS PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
ELI LILLY AND CO - ORFORGLIPRON LOWERS A1C BY 1.3% TO 1.6% IN PHASE 3 TRIAL
ELI LILLY AND CO - REMAINS ON TRACK TO SUBMIT ORFORGLIPRON FOR WEIGHT MANAGEMENT BY END OF YEAR
Source text: ID:nPn2MPJ9Ka
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.